GLP-1 Price Comparison 2026: Every Access Pathway, Actually Priced Out

The number that stopped me: $1,049. That was the cash price for a four-week supply of Wegovy at the pharmacy closest to my house. The number that started me looking: $149. That was the first month of compounded semaglutide from a telehealth provider a colleague had been using for four months.

The gap between those two numbers — over $900 per month, for what is functionally the same active molecule — is not a secret exactly, but it’s also not something the system explains to you unprompted. This article is the explainer I wanted before I started looking.

---

What GLP-1 Medications Are (Short Version)

GLP-1 receptor agonists — semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) — are injectable medications that reduce appetite and slow gastric emptying by mimicking a gut hormone released after eating. They were originally developed for type 2 diabetes management; the weight loss effect was pronounced enough that manufacturers pursued separate approvals for obesity treatment.

Clinical trial data is real and consistent: patients on semaglutide lose an average of 15% of body weight over 68 weeks; tirzepatide trials showed up to 22.5% at the highest doses. These are not supplement numbers. They are pharmaceutical numbers from large randomised controlled trials. Most people reading this already know this. What most people don’t know is what it actually costs to access them.

---

The 4 Access Pathways — Priced Honestly

1. Brand-name with insurance: $0–$50/month (if you qualify — most people don’t)

Wegovy (the brand FDA-approved specifically for obesity) is covered by some commercial insurance plans, but coverage is inconsistent and often requires prior authorisation that demands documented failure of other interventions. Medicare Part D excluded obesity drugs until recently and coverage remains partial and plan-dependent.

If you have employer-sponsored insurance and your plan covers Wegovy or Zepbound, your out-of-pocket cost may be near zero. Novo Nordisk and Eli Lilly both run co-pay assistance programmes that can reduce patient cost to $25/month for commercially insured patients who qualify.

The practical reality: a significant majority of people who want GLP-1 medications for weight loss do not meet insurance coverage criteria, or have plans that exclude obesity drugs entirely. If you’re not diabetic and your employer’s plan doesn’t explicitly cover obesity medication, assume you’re in this group until proven otherwise.

2. Brand-name without insurance: $935–$1,349/month

Cash prices for brand-name GLP-1 medications:

• Wegovy (semaglutide, obesity-indicated): $1,349/month at standard dose
• Ozempic (semaglutide, diabetes-indicated, commonly prescribed off-label): $935–$1,000/month
• Zepbound (tirzepatide, obesity-indicated): $1,059/month
• Mounjaro (tirzepatide, diabetes-indicated): $1,023/month

At these prices, a year of treatment runs $11,000–$16,000. This is the access pathway that has essentially no realistic demand — it exists as a price anchor, and most patients who see these numbers stop there.

3. Compounded via telehealth (no insurance required): $99–$300/month

When a brand-name drug is on FDA shortage — which semaglutide was for an extended period — compounding pharmacies are legally permitted to produce the active ingredient. Even as the shortage status has shifted, a substantial compounded market remains through telehealth platforms that pair physician prescribers with 503B or state-licensed compounding pharmacies.

Compounded semaglutide and tirzepatide are functionally the same active molecule as the brand products, produced at licensed compounding facilities. They are not FDA-approved as finished drug products — the brand products are. That distinction matters for how you evaluate providers: look for 503B-accredited compounding pharmacy partners and documented physician oversight.

This is where the $99–$300 range lives. Dose affects price — starting doses cost less than maintenance doses. Provider platform fees affect price. This is also where most of the realistic demand is.

4. GoodRx and manufacturer coupons: inconsistent, unreliable

GoodRx can reduce the cash price on Ozempic modestly — typically to $850–$950 depending on pharmacy and location. The Novo Nordisk savings card brings commercially insured patients to $25/month but does not apply to uninsured patients. Manufacturer patient assistance programmes exist for very low-income patients but involve income verification and are not designed for the broad market seeking weight management support.

These options are worth checking — GoodRx in particular takes two minutes — but they are not a reliable access pathway for most patients. If you qualify, great. If not, don’t spend three hours chasing coupons before looking at telehealth.

---

Provider Comparison

These are the platforms most commonly used for compounded GLP-1 access. Prices reflect starting-dose entry points; ongoing costs vary by titration.

Provider	Active compound	Starting price	Notable feature
Gala	Tirzepatide	From $179/mo	Oral option available — no needles required
TrimRX	Semaglutide	From $199/mo	3-minute assessment, fast onboarding
Viviomd	Semaglutide (oral dissolving tablet)	From $199/mo	Needle-free formulation, sublingual delivery
Clinic Secret	Semaglutide/tirzepatide	First month heavily discounted	70% off first month entry offer
RightWell	Semaglutide	Varies by plan	Clinical programme with ongoing provider support
Ivim Health	Semaglutide/tirzepatide	Premium tier	Individualized dosing protocols, physician-directed titration
Prime Health	Semaglutide/tirzepatide	Varies	Personalised plans, ongoing check-ins

A few notes on reading this table:

Gala’s tirzepatide from $179/month is one of the more competitive prices in the market for the more potent compound, and the no-needle oral option is genuinely differentiated — many patients who would benefit from GLP-1s avoid injectable medications specifically because of needle aversion.

Viviomd’s oral dissolving tablet is the clearest needle-free option for semaglutide specifically. Oral semaglutide does have somewhat different bioavailability characteristics than subcutaneous injection — the sublingual/dissolving format occupies a different pharmacokinetic profile than the Rybelsus oral pill, which is designed for diabetic glucose management at lower systemic doses.

Clinic Secret’s first-month hook makes sense as a trial entry point if you’re uncertain about committing — though verify the ongoing price before assuming the discount persists.

---

What to Actually Check Before Signing Up

The compounded GLP-1 market has legitimate providers and bad ones. Before entering payment information with any platform, verify:

Physician oversight: Is there a real physician (or NP/PA) reviewing your intake assessment and writing the prescription? Or is it a checkbox system with no meaningful clinical review? A legitimate telehealth GLP-1 provider will have a synchronous or asynchronous consult where a licensed prescriber evaluates your health history.

Compounding pharmacy credentials: Who fills the prescription? A 503B-registered outsourcing facility operates under FDA oversight and cGMP standards. A state-licensed 503A compounding pharmacy is regulated at the state level. Both are legitimate; 503B is the higher standard. Ask the platform which facility fills their prescriptions. If they won’t tell you, look elsewhere.

Cancellation terms: Some platforms bill quarterly upfront. Others lock you into auto-renewal without clear cancellation processes. Read the cancellation policy before subscribing, not after. Look for month-to-month billing options, especially at entry.

What happens when you titrate: Starting doses are cheap. Maintenance doses at 2.4mg semaglutide or 15mg tirzepatide can cost significantly more. Ask each platform for the full titration price schedule, not just the entry price in the marketing.

Refund policy for non-responders: A meaningful percentage of GLP-1 users are non-responders — the medication simply doesn’t produce the expected effect. Know before you commit whether you have any recourse if you spend three months and see no results.

---

The Honest Bottom Line

If you have insurance that covers obesity medication, start there. If you don’t — which describes the majority of patients seeking this treatment — the compounded telehealth pathway at $99–$300/month is the realistic access route.

The $1,000+ gap between brand and compounded is real, and it’s why compounded demand is where it is. Whether that gap persists as FDA shortage designations evolve is genuinely uncertain — which is another reason to compare current pricing across providers rather than committing to one platform long-term without looking.

The comparison page at /best/cant-lose-weight has current pricing from active providers. Prices in this market shift. Check there before making a decision based on any number you read here.